Venous thromboembolism risk and prophylaxis in the acute hospital care setting: report from the ENDORSE study in Egypt
Authors
Goubran, Hadi A.Sholkamy, Sherif
El-Haddad, Alaa
Mahmoud, Alaa
Rizkallah, Mounir A.
Sobhy, George
UMass Chan Affiliations
Center for Outcomes ResearchDocument Type
Journal ArticlePublication Date
2012-09-05Keywords
Venous thromboembolismEgypt
Thromboprophylaxis
Risk factors
Cardiovascular Diseases
Clinical Epidemiology
Epidemiology
Health Services Research
Metadata
Show full item recordAbstract
BACKGROUND: Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However, the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE study in Egypt is part of a global initiative to uncover the incidence of high-risk surgical and medical patients and determine what proportion of these patients receive appropriate VTE prophylaxis. METHODS: Ten Egyptian hospitals participated in this observational study, enrolling all surgical and medical patients that met the study criteria. This resulted in a cohort of 1,008 patients in acute care facilities who underwent a retrospective chart review. Each patient's VTE risk status and the presence or absence of appropriate prophylactic care was assessed according to the American College of Chest Physicians (ACCP) guidelines 2004. RESULTS: Of the 1,008 patients enrolled, 395 (39.2%) were found to be at high-risk for VTE. Overall, 227 surgical patients were at high-risk, although only 80 (35.2%) received ACCP-recommended prophylaxis. Similarly, 55/268 (32.75%) of high-risk medical patients received appropriate VTE prophylaxis. Low molecular weight heparin was the most commonly used anticoagulant, while mechanical prophylactic use was quite low (1.5%) in high-risk patients. CONCLUSIONS: In Egypt, more than one-third of all patients hospitalized for surgery or acute medical conditions are at high risk for developing VTE. However, only a small fraction of these patients receive appropriate VTE prophylaxis. Corrective measures are necessary for preventing VTE morbidity and mortality in these high risk patients.Source
Thromb J. 2012 Sep 5;10(1):20. doi: 10.1186/1477-9560-10-20. Link to article on publisher's siteDOI
10.1186/1477-9560-10-20Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27113PubMed ID
22950681Related Resources
Link to Article in PubMedRights
© 2012 Goubran et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ae974a485f413a2113503eed53cd6c53
10.1186/1477-9560-10-20